Gilead Sciences says studies for coronavirus treatment still inconclusive after unsuccessful trial in China

Credit: Proactive Investors- Published on April 24, 2020
Gilead Sciences Inc (NASDAQ:GILD) said studies for the use of its antiviral drug remdesivir in patients with severe coronavirus are still inconclusive. Hopes for the cure were dashed when the World Health Organization accidentally posted preliminary clinical data from trials in China showing that the drug was not successful....
Advertisement

Video credit: Reuters Studio
Published on April 23, 2020 -  02:04
S&P 500 slips after report on coronavirus drug trial
The S&P 500 ended marginally lower on Thursday after a report that an experimental antiviral drug for the coronavirus flopped in its first randomized clinical trial, denting earlier optimism that the impact of the pandemic on the labor market was nearing an end. Yahaira Jacquez reports.

You are here


Related videos from verified sources

Exclusive: Hospital Launches Clinical Trial After New York Doctor Touts Coronavirus Medication Cocktail 03:23
Credit: CBS 2 New York - Published on April 30, 2020 


State Dept. Spox: Demanding Coronavirus Info From China Not Part of 'Blame Game' 03:02
Credit: Cheddar Inc. - Published on April 30, 2020 


Remdesivir trial shows it is an effective treatment 00:38
Credit: KTNV Channel 13 Las Vegas - Published on April 30, 2020 


Related news from verified sources

Gilead Sciences Inc (NASDAQ:GILD) has posted positive data on the use of its antiviral agent remdesivir for severe coronavirus (Covid-19) patients. The US pharma...
on April 29, 2020 • Proactive Investors

A trial in China testing Gilead Sciences Inc's antiviral drug, remdesivir, in those with mild symptoms of COVID-19 has been suspended due to a lack of eligible...
on April 15, 2020 • Reuters

You might like